Author Response

BJOG. 2025 Nov 11. doi: 10.1111/1471-0528.70078. Online ahead of print.

Maria E Bekkenes^{1

2}, Marte M Jørgensen³, Anne F Jacobsen^{2

4}, Morten W Fagerland⁵, Helene Rakstad-Larsen⁴, Lars Aaberge⁶, Olav Klingenberg^{2

7}, Trude Steinsvik⁸, Lars Asphaug^{9

10}, Leiv Arne Rosseland^{1

2}

¹ Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
² Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
³ Department of Anaesthesia, Akershus University Hospital, Lørenskog, Norway.
⁴ Department of Obstetrics, Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.
⁵ Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.
⁶ Department of Cardiology, Oslo University Hospital, Oslo, Norway.
⁷ Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
⁸ Department of Laboratory Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway.
⁹ Clinical Trials Unit, Oslo University Hospital, Oslo, Norway.
¹⁰ Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.

No abstract available

Keywords: carbetocin; cost‐effectiveness analysis; obstetric haemorrhage.

Publication types